A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00502840
First received: July 17, 2007
Last updated: October 7, 2013
Last verified: October 2013
  Purpose

This single arm study will evaluate the efficacy and safety of repeated courses of MabThera in patients with active rheumatoid arthritis who have participated in ML19070, and have completed the week 24 visit. Eligible patients (DAS28 >2.6 after week 24), will receive 2 infusions of 1g MabThera (Day 1 and day 15). For all patients in this extension study, up to 3 repeated courses of treatment are allowed. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.


Condition Intervention Phase
Rheumatoid Arthritis
Drug: rituximab [MabThera/Rituxan]
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Change of DAS 28 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • ACR 20/50/70, HAQ, SF-36, FACIT-F, TJC, SJC, CRP, BSG, RF. [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • AEs [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 194
Study Start Date: July 2007
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: rituximab [MabThera/Rituxan]
1g iv on days 1 and 15

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients with rheumatoid arthritis who participated in ML19070, and have completed the week 24 visit;
  • eligible for re-treatment (DAS28 >2.6 after week 24, swollen joint count >=4, tender joint count >=4).

Exclusion Criteria:

  • patients who have withdrawn from treatment in ML19070 pre-week 16;
  • patients with a previous response in DAS28 <0.6 to MabThera after week 16;
  • concurrent treatment with any DMARD except for methotrexate, any TNF alpha inhibitor, or other biologic or investigational agent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00502840

  Hide Study Locations
Locations
Germany
Bad Aibling, Germany, 83043
Bad Bramstedt, Germany, 24576
Berlin, Germany, 13055
Berlin, Germany, 14163
Berlin, Germany, 13589
Berlin, Germany, 10117
Berlin, Germany, 13125
Bonn, Germany, 53111
Cuxhaven, Germany, 27476
Donaueschingen, Germany, 78166
Dresden, Germany, 01109
Erfurt, Germany, 99096
Erlangen, Germany, 91054
Essen, Germany, 45239
Frankfurt Am Main, Germany, 60590
Freiburg, Germany, 79106
Fulda, Germany, 36039
Gießen, Germany, 35392
Gommern, Germany, 39245
Hagen, Germany, 58135
Halle, Germany, 06120
Hamburg, Germany, 22081
Hannover, Germany, 30625
Heidelberg, Germany, 69120
Herne, Germany, 44652
Homburg/Saar, Germany, 66424
Jena, Germany, 07747
Karlsruhe, Germany, 76137
Köln, Germany, 50924
Ludwigshafen, Germany, 67063
Mittelherwigsdorf, Germany, 02763
Muenchen, Germany, 80336
München, Germany, 80335
München, Germany, 81541
Münster, Germany, 48149
Naunhof, Germany, 04683
Oldenburg, Germany, 26122
Osnabrück, Germany, 49074
Pirna, Germany, 01796
Ratingen, Germany, 40882
Regensburg, Germany, 93053
Rostock, Germany, 18059
Sendenhorst, Germany, 48324
Stuttgart, Germany, 70178
Treuenbrietzen, Germany, 14929
Tübingen, Germany, 72076
Ulm, Germany, 89081
Wiesbaden, Germany, 65189
Wuerzburg, Germany, 97080
Würselen, Germany, 52146
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00502840     History of Changes
Other Study ID Numbers: ML19071
Study First Received: July 17, 2007
Last Updated: October 7, 2013
Health Authority: Germany: Paul-Ehrlich-Institut

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Rituximab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 20, 2014